Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

DEERFIELD, Ill. and OSAKA, Japan, Sept. 4, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis. A BLA was submitted in June 2013 seeking approval for vedolizumab for the treatment of adults with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC). The application submitted for vedolizumab for the treatment of adults with moderately to severely active CD will be reviewed by the FDA under the standard review timeline.  

An application can receive Priority Review designation if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. Priority Review status allows for an eight month review period from the date of submission, compared to the standard review period of 12 months.

"Additional treatment options are needed for ulcerative colitis, and the acceptance for Priority Review of vedolizumab underscores this need," said Karen Lasch, M.D., medical director - GI, Medical Affairs, U.S. Region, Takeda. "Takeda is excited about the potential for vedolizumab and, if approved, the possibility of providing a new treatment option for people with CD and UC."

CD and UC are the two most common types of inflammatory bowel disease (IBD), and can be both painful and debilitating, sometimes leading to serious complications. While CD and UC treatment options are available, many patients may not achieve or maintain remission of their disease. 
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
(Date:7/30/2015)... July 30, 2015   Gaumard® Scientific Company ... UNI®, the world,s first operating system to support ... available exclusively to Gaumard users. UNI® version 2.27.21.0 ... Newborn Tory™ S2200, as well as improvements to ... clinical measures such as EtCO 2 .  ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
... WASHINGTON, Sept. 29, 2011 As small businesses struggle ... indicates concern that forthcoming Essential Health Benefits regulations ... drug companies to raise prescription drug costs, the ... benefit managers (PBMs) administer drug benefits for thousands of ...
... 29, 2011 A drug recently approved by the U.S. ... targets a malfunctioning gene discovered more than a decade earlier ... scientific findings from St. Jude can be translated into therapies ... adults. The drug is Xalkori (crizotinib). The FDA ...
Cached Medicine Technology:Some Essential Benefits Rules Could Worry Small Businesses 2St. Jude Children's Research Hospital Discovery Aided Quest for Adult Cancer Drug 2St. Jude Children's Research Hospital Discovery Aided Quest for Adult Cancer Drug 3
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s ... It was also the first provider of Exilis non-surgical fat reduction in New York. ... it has attracted a large International clientele. Many patients travel to New York ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
(Date:7/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of ... Aesthetics released this new applicator in the United States as an upgrade to the ... The original applicator required a 2 hour treatment time. The new CoolSmooth ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... workshop at its new True North Conference Center. The medical community, social workers, ... Jacksonville community may be more aligned in the effort to better understand and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their flagship Organic ... the 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington ... sugar” on the market, is a natural choice given the Open’s commitment to sustainable ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... known that pregnant women who develop pre-eclampsia, which are a ... the risk of having a stroke during pregnancy. // ... Centres for Disease Control and Prevention now report that pre-eclampsia ... ,Dr David W. Brown and colleagues in Atlanta used ...
... rejected the UN findings that claim an extra 4,000 cancer ... Chernobyl disaster,// which struck 20 years ago. Instead, the group ... 93,000. ,Most of these victims would ... in April 1986 was one of the worst nuclear accidents ...
... Generally Vitamin D is found in either sunrays or in ... for that. // The research says that brief UV exposure ... D. The Food and Drug Administration proposed study is being ... to the concern with the vitamin deficiency. It would be ...
... died and up to 25,000 affected in a malaria epidemic in ... fanned out to take preventive steps and cure those hit by ... ,The minister said 50 people had died of cerebral malaria since ... Golaghat being the worst hit. ,"We have been able ...
... April issue of Archives of Dermatology, almost 50% of high ... their newspapers. // Tanning advertisements have been found in newspapers ... were about 40 tanning advertisements, 15 of whom did speak ... months. ,The article carries related information about the ...
... the lifestyle and socioeconomic status of 422 students with reference ... who lack sleep tend to be overweight //. ... Laval's faculty of medicine and was based on a telephonic ... children’s body mass index revealed that 24% of the girls ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: